related documents
- A randomized trial of 79.2Gy versus 70.2Gy radiation therapy (RT) for localized prostate cancer. Conferences
- Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC). Conferences
- Benefit of Whole-Pelvis Radiation for Patients With Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis. Conferences
- C-reactive protein as a prognostic factor in advanced urothelial carcinoma receiving chemotherapy or immunotherapy. Conferences
- CD73 expression in primary and metastatic renal cell carcinoma (RCC). Conferences
- Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials. Conferences
- Canadian Cancer Trials Group HE.1: A phase III study of palliative radiotherapy for symptomatic hepatocellular carcinoma and liver metastases. Conferences
- Cell surface GRP78 activation by anti-GRP78 autoantibodies in relation to prostate tumour growth via tissue factor activation. Conferences
- Effect of anti-GRP78 autoantibodies on prostate cancer progression through tissue factor procoagulant activity. Conferences
- Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma. Conferences
- IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone. Conferences
- Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy. Conferences
- Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy. Conferences
- Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy. Conferences
- Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC). Conferences
- Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials. Conferences
- Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy. Conferences
- Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. Conferences
- Incidence, characteristics, and implications of thrombo-embolic events in patients with urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy. Conferences
- Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC). Conferences
- NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer. Conferences
- NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA. Conferences
- New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab. Conferences
- Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma. Conferences
- Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study. Conferences
- Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium Conferences
- Outcomes of advanced urothelial carcinoma following discontinuation of programmed death (PD)-1 or PD-ligand (L)-1 inhibitors. Conferences
- Pain palliation as an oncology label indication: Lessons learned in custirsen phase III development. Conferences
- Patterns of prostate cancer management across Canadian prostate cancer treatment specialists. Conferences
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). Conferences
- Prognostic impact of C-reactive protein (CRP) in metastatic prostate cancer (MPC): A systematic review and meta-analysis. Conferences
- Real world patterns of treatment sequencing in Canada for metastatic castrate-resistant prostate cancer. Conferences
- Renal cell carcinoma (RCC) primary tumor shrinkage on vascular endothelial growth factor (VEGF)-targeted therapy (TT): A pooled analysis. Conferences
- Statin use and outcomes of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) being treated with abiraterone (Abi). Conferences
- The RADICAL-PC trial. Conferences
- The proportion and characterization of patients with metastatic renal cell carcinoma who are never treated or have delayed treatment with targeted therapy: Results from a large prospective cohort. Conferences
- The role of FSH in castration-induced adipogenesis and cardiovascular diseases: Highlighting differences between orchiectomy, GNRH agonists, and antagonists. Conferences
- Transurethral (TURP) biopsy of suspected anterior prostate cancers identified by MRI: Pilot study of a novel technique. Conferences
- Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation (TMT): An international collaboration. Conferences